Investor Presentaiton

SELECT TRIALS - EARLY PHASE DIABETES AND OBESITY Lilly Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Lepodisiran (LPA siRNA) NCT05565742 Lipoprotein A Study of LY3819469 in Participants With Elevated Disorder Lipoprotein(a) [Lp(a)] (ALPACA) 2 254 Percent Change from Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Oct 2023 Oct 2024 Muvalaplin NCT05563246 Lipoprotein Disorder A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (KRAKEN) 2 233 Percent Change from Baseline in Lipoprotein (a) Lp(a) Jan 2024 Jan 2024 Solbinsiran NCT05256654 Dyslipidemias A Study of LY3561774 in Participants With Mixed Dyslipidemia (PROLONG-ANG3) 2 175 Percent Change from Baseline for Apolipoprotein B (ApoB) Mar 2024 Jun 2024 Relaxin-LA NCT05592275 Heart Failure A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFPEF) 2 432 Change from Baseline in Left Atrial Reservoir Strain (LARS) Nov 2024 Jan 2025 * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Source: clinicaltrials.gov, August 1, 2023 2023 Q2 EARNINGS 51

View entire presentation